Frontlight ResearchEarly access
Not yet recruitingPhase 2
Substudy to Evaluate the Potential Treatment Effect of the ABBV-7066 (risankizumab/ABBV-701) Combination Compared to Each Respective Monotherapy in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
Key facts
- Who runs it
- AbbVie Deutschland GmbH & Co. KG
- Where
- Belgium9 sites in 1 countryChoose a country to see its sites
- Trial code
- EU 2026-525960-16-00
- NCT07697456
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 13 people, planned
- Starts
- 15 Dec 2026
- Expected to end
- 10 Mar 2031
- Type of study
- Interventional
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Crohn's Disease specific: Crohn's Disease Activity Index (CDAI) score of ≥ 220
- Crohn's Disease specific: Confirmed diagnosis of CD at least 90 days prior to Baseline
- Crohn's Disease specific: Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of ≥ 6 for ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease
- Crohn's Disease specific: Demonstrated failure of 1 or more therapy for CD
- Ulcerative Colitis specific: Confirmed diagnosis of UC at least 90 days prior to Baseline
- Ulcerative Colitis specific: Active UC with a modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore (ESS) of 2 to 3
- Ulcerative Colitis specific: Demonstrated failure of 1 or more therapy for UC
Who cannot take part
- Participants with demonstrated intolerance to p19 IL-23 inhibitors (including risankizumab)
- Participants treated with any investigational drug within 30 days or 5 halflives of the study treatments (whichever is longer) prior to the first dose of study treatment
- Participants who received any ATs (biologic or small molecules) prior to first dose of study treatment within the protocol specified time frame
- Participants with surgical bowel resection within the past 3 months prior to Baseline
- Crohn's Disease specific: Participants with >3 prior bowel resections
- Crohn's Disease specific: Participants with previous small bowel resection(s) of combined length >100 cm
- Ulcerative Colitis specific: Participants with prior colectomy (total or subtotal)
- Ulcerative Colitis specific: Participants with extent of disease limited to < 10 cm of rectum
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Substudy 2: To evaluate efficacy and safety of the ABBV-7066 (risankizumab/ABBV-701) combination compared to the respective monotherapy component in adult subjects with moderately to severely active CD or UC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
- Record updated
- 17 November 2026